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ABSTRACT
Central nervous system (CNS) involvement in systemic B-cell non-Hodgkin lymphoma (B-NHL) at
diagnosis (sysCNS) is rare. We investigated the outcome of 21 patients with sysCNS, most com-
monly diffuse large B-cell lymphoma, treated with high dose methotrexate (HD-MTX) and
R-CHOP. The median number of cycles of HD-MTX and R-CHOP was 4 (range 1–8) and 6 (range
0–8), respectively. Consolidative whole brain radiotherapy (WBRT) was given to 33% (7/21)
patients. With a median follow-up of 44 months the 3-year progression free survival (PFS) and
overall survival (OS) were 45% (95%CI 34–56%) and 49% (95%CI 38–60%), respectively. Over
90% of patients had an unfavorable international prognostic index score, reflected by treatment-
related mortality of 19% (4/21) and relapse-related mortality of 28% (6/21). The outcome of
these patients was, however, unexpectedly good when compared to secondary CNS relapses.
Prospective studies are needed to define the optimal treatment for patients with sysCNS, but its
rarity might be challenging.
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Introduction
The risk of central nervous system (CNS) dissemination
of aggressive B-cell lymphoma (B-NHL) is 5% [1]. High
international prognostic index (IPI) score, kidney or
adrenal gland involvement and diffuse large B-cell
lymphoma (DLBCL) with dual expression of MYC and
BCL2 by immunohistochemistry convey a high risk of
CNS relapse [2,3]. In the majority, CNS involvement
occurs during progression of the disease. Rarely, CNS
dissemination is already present at initial diagnosis.
Unlike the general favorable outcome of patients with
primary CNS lymphoma (PCNSL) when treated with
high dose methotrexate (HD-MTX), cytarabine and thi-
othepa [4–7], CNS relapse of aggressive B-NHL conveys
a dismal prognosis [8,9]. Salvage regimens with
relapsed PCNSL incorporating thiothepa and high dose
chemotherapy followed by autologous stem cell trans-
plantation (ASCT) showed an improved overall survival
(OS) for these patients if initially responsive and subse-
quently eligible for intensive treatment [10,11].
It is unknown if the prognosis of concomitant sys-
temic and parenchymal CNS B-NHL at diagnosis
(sysCNS B-NHL) is different from secondary CNS lymph-
oma in the relapse setting. Given its rarity, data on
treatment for sysCNS B-NHL are sparse and there is no
established standard of care. Recent data from two
studies suggest a beneficial effect of intensive chemo-
therapy followed by ASCT [12,13]. In both studies,
ASCT was only offered to patients in complete
remission (CR) (31%–50%). Furthermore, in one of the
studies, anthracyclines – highly effective in systemic
B-NHL – were only a minor part of the induction
regimen [13]. Outcome of non-transplant strategies
in sysCNS B-NHL was only explored in small series
[14,15].
We observed an excellent response in a patient
with sysCNS initially treated as if primary CNS with the
European Organisation for Research and Treatment of
Cancer (EORTC) regimen MBVP (methotrexate, etopo-
side, carmustine and prednisolone) [5]. In this patient,
not only the CNS component responded well, but also
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systemic involvement responded at the same time.
Consequently, we continued after MBVP with rituxi-
mab, cyclophosphamide, doxorubicin, vincristine and
prednisolone (R-CHOP), and applied this regimen to
the next series of patients. Simultaneously, another
University Medical Center in the Netherlands com-
bined R-CHOP alternating with HD-MTX, based upon
the same observations.
Therefore, we retrospectively investigated the out-
come of patients with sysCNS B-NHL treated in both
centers with a combination of drugs effective for CNS
and systemic involvement. None of these patients
underwent ASCT.
Methods
Study design and patient identification
Clinical data on patients with sysCNS B-NHL were
retrieved from the electronical databases of two refer-
ral medical centres in the Netherlands. All patients had
newly diagnosed, histologically proven aggressive
B-cell lymphoma. In case of transformed lymphoma,
patients had not received prior therapy. CNS involve-
ment was determined either by biopsy, magnetic
resonance imaging (MRI) and/or CSF examination.
Patients had been treated between 2000 and 2015.
Patients should have received at least one cycle of
HD-MTX. Both regimens start with a cycle of HD-MTX.
The pathological assessment was performed by experi-
enced hematopathologists. Since patients were treated
according to best practice no medical ethical commit-
tee approval was required.
Treatment and follow-up
Initial assessment
Staging consisted of computed tomography scan of
neck, chest, abdomen and pelvis, bone marrow biopsy,
cerebrospinal fluid (CSF) examination with four-color
flow cytometry (FCM), MRI brain, and further investiga-
tions if clinically indicated. A fluorodeoxyglucose
(18F-FDG) positron emission tomography scan was
available for all patients treated at one of the medical
centres. Systemic B-NHL was diagnosed by lymph
node or tissue biopsies in all cases. CNS involvement
was diagnosed either by brain biopsy or CSF flow
cytometry in 58% (12/21) of patients. In 42% (9/21)
neurological symptoms and parenchymal abnormal-
ities on the MRI scan were considered sufficient for
the diagnosis of CNS involvement. In 10% (2/21) CNS
involvement presented as neurolymphomatosis. In all
patients the international prognostic index (IPI) was
documented.
Treatment
Patients were treated according to one of two regi-
mens. At the University Medical Centre Groningen a
sequential regimen was adopted. Four cycles of MTX
at a dose of 3 g/m2 were given as part of the MBVP
regimen, which also includes carmustine (100mg/m2
at day 4), teniposide (100mg/m2 at day 2 and 3) and
prednisolone (60mg/m2 at day 1–5) [5]. Interim
response evaluation was performed after completion
of HD-MTX. Patients with a partial CNS remission
received whole brain radiotherapy (WBRT) at this
point. Patients subsequently continued for 6 cycles
of R-CHOP after which end-of-treatment evaluation
took place. R-CHOP was given as a combination of
rituximab (375mg/m2 at day 1), cyclophosphamide
(750mg/m2 at day 1), doxorubicin (50mg/m2 at day
1), vincristine (1.4mg/m2 at day 1 up to a maximal
dose of 2mg) and prednisolone (100mg at day 1–5).
At the Erasmus Medical Centre Rotterdam an alternat-
ing regimen was adopted, which consisted of 6 alter-
nating cycles of HD-MTX at a dose of 3 g/m2 and
R-CHOP. Interim evaluation was performed after 3
cycles and end-of-treatment evaluation after comple-
tion of therapy. Patients with a partial remission (PR)
of the CNS involvement received WBRT. In both regi-
mens patients with leptomeningeal involvement
received intrathecally methotrexate and/or cytarabine
until complete clearance of the CSF as assessed by
FCM. Furthermore, 4 patients in the alternating regi-
men received i.t. therapy without a positive CSF
because of local practice.
Response assessment
Response was evaluated according to the 1999 con-
sensus criteria for systemic NHL and the consensus cri-
teria for PCNSL [16,17]. Tumor response was classified
as CR, PR, stable disease (SD), or progressive disease
(PD). Only patients in complete remission at CNS and
systemic sites at the end of treatment were reported
as a CR. Treatment related mortality (TRM) was defined
as death during or 3 months after treatment.
Follow-up was completed until February 2016.
Statistical analysis
Duration of follow-up was calculated for all patients
alive.The primary endpoints were OS and progression
free survival (PFS). OS was defined as time from diag-
nosis until death (from any cause); PFS as the time
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from diagnosis until relapse, progression or death
(from any cause). Survival curves were estimated
according to the Kaplan–Meier method. Between-
group differences in OS and TTP were evaluated using
the log-rank test. All categorical variables were
expressed as counts and percentages. Where applic-
able, differences between groups were evaluated by
chi-square for binary variables and independent T-tests
for continuous variables. A two-tailed p-value of less
than 0.05 indicated statistical significance. All analyses
were performed using IBM SPSS Statistics version 22
(IBM Corp., Armonk, NY).
Results
Clinical characteristics
Between 2000 and 2015 21 sysCNS B-NHL patients
were treated. Demographic data from the patients in
the two treatment regimens are presented in Table 1.
Diffuse large B-cell lymphoma composed the major
histological B-NHL entity (66%). The median age was 54
years (range 19–71 years) with a slight female prepon-
derance. Two-third of patients had a WHO performance
score 2 and 91% of patients had an intermediate or
high IPI-score. A large number of patients had lymph-
oma infiltration of organs known to convey a high risk
of CNS relapse, like testicles (44% of patients at risk),
bone (38%), kidney (19%) and breast (17% of patients
at risk). Besides parenchymal CNS, concomitant CSF
involvement was present in 43% of patients.
Treatment
Thirteen patients (62%) completed therapy with only
minor deviations. Two patients received less than 6 R-
CHOP cycles. One patient had both a reduction in the
number of MTX and R-CHOP cycles. Data on treatment
intensity between the two treatment regimens are pre-
sented in Table 2. Detailed information on individual
treatment and response assessment is shown in
Supplementary Figure 1. The median number of HD-
MTX cycles was 4 (range 1–8). Thirteen patients (62%)
received concomitant intrathecal MTX. The median
number of R-CHOP cycles was 6 (range 0–8). WBRT
was given to 7 patients (33%), all because of persistent
abnormalities on brain MRI. One patient received local
radiotherapy on an extracranial site because of PR at
the end of treatment. Besides the additional VP16 and
BCNU in patients treated with MBVP, there was no sig-
nificant difference between the two regimens.
Follow-up, response and survival
The median duration of follow-up of patients was 44
months (range 5–104). The overall response rate (ORR)
at the end of treatment was 62%: CR 57% (n¼ 12) and
PR 5% (n¼ 1). PD was noted in 19% (n¼ 4), whereas
early TRM due to infectious complications was
observed in 19% (n¼ 4). All infectious complications
occurred during neutropenia. Two patients died as a
consequence of an aspiration pneumonia due to
neurogenic dysphagia. One patient developed a com-
plicated clostridium difficile infection after prolonged
treatment with ciprofloxacin. One patient died of a
complicated meningitis (Klebsiella pneumoniae), which
was not related to a previous lumbar puncture. One
patient died 6 months after treatment as a result of
cognitive deterioration.
Table 1. Clinical characteristics at diagnosis of the 21 patients
with concomitant systemic and parenchymal central nervous
system B-cell non-Hodgkin.
Characteristics
Sequential
MBVP/R-CHOP
Alternating
MTX/R-CHOP
Patients (n) 10 11
Median age 54 (41–60) 59 (19–71)
Gender (M/F) 2/8 7/4
B-cell lymphoma
Diffuse large B-cell lymphoma (%) 5 (50) 9 (82)
Iatrogenic immunodeficiency lymphoma (%) 2 (20) 1 (9)
Transformed marginal zone lymphoma (%) 2 (20) 0 (0)
Intravascular B-cell lymphoma (%) 1 (10) 1 (9)
Extra CNS involvement
Testicular (%)a 0 (0) 4/7 (57)
Breast (%)a 2/8 (25) 0 (0)
Bone/bone marrow (%) 6 (60) 2 (18)
Kidney/lung (%) 4 (40) 0 (0)
Cerebrospinal fluid involvement (%) 4 (40) 4 (45)
Elevated LDH (%) 6 (60) 6 (54)
WHO performance
1–2 (%) 2 (20) 5 (45)
3–4 (%) 8 (80) 6 (55)
IPI-score
1 (%) 1 (10) 1 (9)
2–3 (%) 7 (70) 7 (64)
4–5 (%) 2 (20) 3 (27)
aPercentage in patients at risk.
Testicular involvement can only be observed in male patients. Breast
involvement can only be observed in female patients.
Table 2. Treatment intensity in the 21 patients with concomi-
tant systemic and CNS B-NHL at diagnosis.
Characteristics
Sequential
MTX/R-CHOP
Alternating
MTX/R-CHOP
Patients (n) 10 11
Median MTX cycles (n) 4 (2–6) 5 (1–8)
Median cumulative MTX dosing (gr) 12 (6–18) 15 (3–24)
Median i.t. MTX cycles (n)a 6 (4–10) 9 (4–13)
Median CHOP cycles (n) 6 (0–6) 6 (1–8)
Rituximab (%) 10 (100) 10 (90)
Additional chemotherapy Teniposide Carmustine n.a.
Radiotherapy in PR (%) 3 (30) 4 (36)
aIn patients receiving i.t. therapy.
Number of i.t. cycles only described for patients receiving intrathecal
therapy.
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Three-year PFS and OS for the entire cohort were
45% (95%CI 34–56%) and 49% (95%CI 38–60%),
respectively (Figure 1(A,B)). No significant differences
in PFS and OS were found between both regimens
(HR OS 1.25, 95%CI 0.38–4.2; p 0.72). Although statis-
tical analysis showed no significant differences in out-
come between the various variables due to the small
number of patients, all patients (n¼ 3) with IPI-score
0–1 were alive at follow-up, whereas all patients
(n¼ 4) with IPI-score 4–5 died within 2 years after
diagnosis.
The combined incidence of refractory and relapsed
sysCNS was 28% (6 of 21 patients). The relapse rate in
patients achieving a CR was only 8% (1 of 12 patients),
which is reflected by the plateau after 12 months in
the PFS and OS curves (Figure 1(A,B)). Patients in CR/
PR had a 3-year PFS and OS of 74% and 83%, respect-
ively (Supplementary Figure 2(A,B)) The patient who
relapsed did so within a year in the CNS. She subse-
quently received WBRT but died soon afterwards. The
one patient in PR progressed after 8 months with both
systemic and CNS involvement. He received no further
therapy and died shortly thereafter. The four patients
with PD all died within 6 months. The site of progres-
sion was systemic-only in two patients, CNS-only in
one patient and concomitant systemic and CNS in one
patient.
Discussion
By combining the results from two medical referral
centres in the Netherlands, we performed the second
largest retrospective study in patients with sysCNS
B-NHL. Findings from this study indicate that non-
transplant regimens of HD-MTX and R-CHOP can be an
effective treatment for sysCNS B-NHL. With a 3-year OS
of 49% the outcome in our cohort is comparable to
the more intensive regimen including ASCT, which is
available to only a selected group of patients (5-year
OS 41%) [13]. In one of the three studies with non-
transplant regimens 4 out of 6 (67%) patients achieved
a CR when treated with HD-MTX and R-CHOP. In a
second study with HD-MTX, rituximab, cytarabine and
idarubicin (R-IDARAM) 4 out of 10 (40%) patients
achieved a CR. Median OS of both studies was 25.1
months and more than 30 months, respectively
[14,18]. In a pilot study with dose-adjusted EPOCH
(etoposide, cyclophosphamide, doxorubicin, vincristine,
prednisone) plus rituximab 8 out of 8 patients
achieved a CR [15]. Four patients underwent a consoli-
dative autologous stem cell transplantation. With a
median follow up of 11 months all patients were alive.
In most of our patients systemic involvement
included one or more organs known to convey a high
risk of CNS involvement in systemic B-NHL [1]. In par-
ticular 4 patients had renal involvement, which is the
strongest risk factor for CNS relapse in DLBCL [3].
These findings suggest an early dissemination of a sys-
temic B-NHL, rather than a systemic manifestation of a
PCNSL. This might be important, since PCSNL has sev-
eral pathological features that are only infrequently
present in systemic DLBCL, such as a high incidence of
mutations in CD79B and MYD88, loss of human leuko-
cyte adhesion (HLA) molecules and frequent expres-
sion of the programed death ligand 1 [19–21]. Despite
its similarity with systemic B-NHL, the OS of sysCNS
Figure 1. (A) OS and (B) PFS of 21 patients with concomitant systemic and parenchymal CNS B-NHL at diagnosis.
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B-NHL treated with HD-MTX and R-CHOP was better
than expected and comparable to that of PCNSL and
certainly not as bad as secondary relapsed CNS B-NHL
treated with HD-MTX and cytarabine (Supplementary
Table 1) [4–6,8].
The TRM in our cohort of 19% was high, and
reflects the very unfavorable risk profile of our patients
with 67% having a WHO performance of 3–4 and 14%
being older than 65-years. Given the small numbers it
cannot be answered whether the concomitant sys-
temic involvement or additional R-CHOP played a role.
Despite the limited number of relapses, two obser-
vations were interesting: firstly, all but one patient
who relapsed did so less than 6 months after the end
of treatment. All other patients who failed did so dur-
ing the early phase of treatment; secondly, in refrac-
tory and relapsing patients the majority had systemic
progression. The incidence of refractory/early progress-
ing patients in our cohort (24%) was similar to that of
more intensive regimens (35%) [13]. This means that
progressive patients have a dismal outcome and are
unlikely to be salvaged. It is interesting to speculate
whether drugs such as bendamustine, ibrutinib, check-
point inhibitors and lenalidomide would be effective
in this setting, since these drugs generally have a
favorable toxicity profile, known activity in relapsed
systemic B-NHL and CNS penetration [22–26].
Notably, patients who obtain a CR have an excellent
outcome and probably will not benefit from additional
high dose therapy, especially those patients with a low
IPI at start. This challenges the role of consolidation as
suggested by the French lymphoma group LYSA, that
showed a positive impact of high-dose therapy fol-
lowed by autologous stem cell transplantation on 3-
year OS and PFS [12]. However, in our series 7 of 21
patients (33%) received consolidative radiotherapy.
The indirect answer if ASCT can replace WBRT will
have to come from the analysis of the IELSG32 trial,
where patients with a chemosensitive PCNSL were
randomized in a second randomization to WBRT or
ASCT [7]. But even then we have to be cautious to
extrapolate these findings to sysCNS, since PCSNL has
a different biology.
Our study obviously has limitations. Firstly, its retro-
spective nature has inherent known and unknown
biases. We have no information on the outcome of
those patients with synCNS lymphoma who were con-
sidered too frail for referral to our university centers.
This means that our data might be based upon a
selection of those patients fit for high dosed metho-
trexate. Furthermore, although the rationale behind
the treatment was the same, e.g. the combination
of primary CNS treatment followed by systemic
immunochemotherapy, there was a considerable het-
erogeneity in the treatment received. Some patients
were treated with a sequential MBVP/R-CHOP and
others with an alternating HD-MTX/R-CHOP regimen.
Although we observed no significant difference
between the regimens in OS, we cannot assess the
separate effect of teniposide and carmustine. In add-
ition, 7 of 21 patients were unable to complete treat-
ment as planned (Supplementary Figure 1). Except for
gender and associated testicular or breast localization
we observed no significant differences in clinical char-
acteristics or outcome. Given its rarity, sysCNS B-NHL
comparative studies can only be performed in a large,
international multicentre setting. Lastly, high dose
cytarabine and thiothepa were not part of the treat-
ment regimens, although in PCNSL the addition
improved outcome in a randomized phase II study [7].
Whether the addition of cytarabine or thiothepa in
sysCNS B-NHL is feasible remains to be established,
but might be offset by the TRM.
Conclusions
In this second largest cohort of patients with sysCNS
lymphoma at presentation described to date, the out-
come of patients treated with HD-MTX and R-CHOP
was excellent for those patients who obtained a com-
plete remission. This challenges the fact that these
patients are excluded from most trials, and usually are
considered as having a dismal prognosis. Prospective
studies are needed to define the optimal treatment for
these patients.
Potential conflict of interest: Disclosure forms pro-
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